Neutralization assays using the BZ167 strain of human immunodeficiency virus type 1

Comment

. 1997 Nov;176(5):1410-2.

doi: 10.1086/514134.

Comment

J P Moore et al. J Infect Dis. 1997 Nov.

. 1997 Nov;176(5):1410-2.

doi: 10.1086/514134.

No abstract available

Comment on

Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines.
Zolla-Pazner S, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, Clements ML, Duliege AM, Excler JL, Hioe C, Kahn J, McElrath MJ, Sharpe S, Sinangil F, Steimer K, Walker MC, Wassef N, Xu S. Zolla-Pazner S, et al. J Infect Dis. 1997 Apr;175(4):764-74. doi: 10.1086/513969. J Infect Dis. 1997. PMID: 9086128 Clinical Trial.

Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.
Polonis VR, de Souza MS, Darden JM, Chantakulkij S, Chuenchitra T, Nitayaphan S, Brown AE, Robb ML, Birx DL. Polonis VR, et al. J Virol. 2003 Aug;77(15):8570-6. doi: 10.1128/jvi.77.15.8570-8576.2003. J Virol. 2003. PMID: 12857927 Free PMC article.
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
Dong M, Zhang PF, Grieder F, Lee J, Krishnamurthy G, VanCott T, Broder C, Polonis VR, Yu XF, Shao Y, Faix D, Valente P, Quinnan GV Jr. Dong M, et al. J Virol. 2003 Mar;77(5):3119-30. doi: 10.1128/jvi.77.5.3119-3130.2003. J Virol. 2003. PMID: 12584337 Free PMC article.